Linus Pauling won two Nobel Prizes – one for chemistry in 1954, one for peace in 1962 – and then spent the final chapter of his career making an argument that most of his peers found embarrassing. He believed that megadoses of vitamin C could help people with cancer live longer. When he died of prostate cancer at 93, the medical establishment largely used it as a punchline. The brilliant scientist who had reshaped our understanding of chemical bonds had apparently chased a fantasy to his grave.
Fifty years later, it’s not that simple. Researchers are revisiting Pauling’s central claim and finding something unexpected: he wasn’t entirely wrong. He was just using the wrong delivery method, and nobody noticed the difference until decades had passed.
Why the First Trials Got It Wrong
Pauling collaborated with Scottish physician Ewan Cameron in the 1970s on vitamin C cancer treatment research. They gave cancer patients vitamin C first as a drip into a vein, then as tablets. The results from those early patients looked promising. Then the Mayo Clinic conducted two large, well-designed randomized controlled trials of vitamin C in pill form and found no such benefits. Vitamin C was filed away alongside other dismissed “alternative” remedies, and Pauling’s reputation in this area was effectively buried.
But a drip into a vein can raise blood levels to tens or even hundreds of times higher than tablets can. Pauling and Cameron had started with IV administration. The Mayo Clinic trials used tablets only. These were not replications of the same experiment – they were testing fundamentally different things, and nobody made that case clearly enough at the time.
The body tightly controls plasma concentrations of vitamin C when it’s taken orally. Once you reach a modest daily dose, the gut simply stops absorbing more. You can swallow as many capsules as you like, and the level in your blood plateaus. Intravenous vitamin C can reach blood concentrations 30 to 70 times higher than equivalent oral doses. At those concentrations, vitamin C doesn’t behave the way most people think of it.
How High-Dose Vitamin C May Target Cancer Cells
At everyday levels, vitamin C acts as an antioxidant – it mops up harmful molecules and protects cells. At very high concentrations, it can generate hydrogen peroxide, a reactive substance that damages tissue and DNA.
Tumor cells are much less capable of neutralizing hydrogen peroxide than normal cells. The enzyme responsible for breaking it down is catalase, and its activity is often low in cancer cells. Researchers at the University of Iowa found that cells with lower catalase activity were more susceptible to damage and death when exposed to high-dose vitamin C. Cancer cells, already under metabolic stress from rapid growth and often-poor blood supply, are disproportionately vulnerable.
Normal cells, which are under less strain and have better defenses, are more likely to survive. When intravenous vitamin C reaches pharmacologic levels of 20 to 30 millimolar in the blood, it behaves less like a supplement and more like a targeted, tumor-selective agent – something oral doses cannot replicate.
Read More: This Leaf Extract has 400 Times More Antioxidant Power Than Vitamin C
What the Clinical Trials Are Showing
The most compelling human data on vitamin C cancer treatment comes from a research program at the University of Iowa, funded by a grant from the National Cancer Institute. Dr. Joseph Cullen, MD, professor of surgery and radiation oncology, led a randomized Phase 2 trial in patients with late-stage metastatic pancreatic cancer, one of the hardest cancers to treat. Adding high-dose intravenous vitamin C to chemotherapy doubled overall survival from eight months to 16 months, and progression-free survival also improved significantly.
Patients who received vitamin C were able to tolerate higher doses of chemotherapy for longer periods.
The picture is not uniformly positive. The trials that have shown benefit remain relatively small. IV vitamin C alone is not a cure for cancer. In the University of Iowa studies, it was added to support existing chemotherapy – not used as a replacement. Larger confirmatory trials are needed before high-dose IV vitamin C can be considered a standard-of-care adjunct.
What This Means
IV vitamin C in these studies was used as an adjunct to chemotherapy and radiation – not a stand-alone treatment – and it is not a harmless wellness infusion to be administered casually. People with poor kidney function or certain inherited conditions involving red blood cell enzymes face specific risks, and any infusion therapy requires a clinical setting and medical supervision.
If you or someone you know is dealing with a cancer diagnosis, the most useful step is to ask an oncologist specifically whether IV vitamin C has been studied in combination with the proposed treatment. Researchers are examining whether it might reduce chemotherapy side effects across a range of cancers, and some cancer centers are already incorporating it into trials.
The Bottom Line
Linus Pauling was not vindicated wholesale. His push for oral megadoses was the wrong application of a partially correct idea. The core of what he was reaching for – that vitamin C at extreme concentrations might selectively damage cancer cells – has turned out to be biochemically real, even if the mechanism took decades to map and the delivery method he initially championed was the wrong one.
The research that exists now wouldn’t exist if scientists hadn’t eventually asked why the IV route mattered. Ask your oncologist whether any active trials at your treatment center include pharmacological ascorbate as an adjunct.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: One Common Vitamin Could Lower Toxic Alzheimer’s Proteins, Research Suggests